Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
About ATTAIN-1, ATTAIN-2 and ATTAIN clinical trial program ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg and 17.2 mg as a monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
Insight #2 The Five-Factor Mental Model: What Really Drives a Drugs Success
Answer You can check the status of your order anytime by logging into your account and going to the "Orders" section
Women clear GLP-1 agonists more slowly than men
[PubMed | ClinicalTrials.gov | DOI] References and Further Reading Jastreboff AM, et al
